Creative Medical Technology Holdings, Inc. (CELZ)
NASDAQ: CELZ · Real-Time Price · USD
2.000
+0.010 (0.50%)
May 2, 2025, 4:00 PM EDT - Market closed

Company Description

Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States.

The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness.

It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, which is in IND-enabling phase, to treat infertility as a result of premature ovarian failure; iPSCelz, which is in pre-clinical stage, a platform to make cell type in the body; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment.

In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson’s disease.

Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Creative Medical Technology Holdings, Inc.
Creative Medical Technology Holdings logo
Country United States
Founded 1998
Industry Biotechnology
Sector Healthcare
Employees 4
CEO Timothy Warbington

Contact Details

Address:
211 East Osborn Road
Phoenix, Arizona 85012
United States
Phone (480) 399-2822
Website creativemedicaltechnology.com

Stock Details

Ticker Symbol CELZ
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001187953
CUSIP Number 22529Y200
ISIN Number US22529Y4089
Employer ID 87-0622284
SIC Code 2836

Key Executives

Name Position
Timothy Warbington Co-Founder, Chairman, President and Chief Executive Officer
Donald F. Dickerson MBA Senior Vice President, Chief Financial Officer and Director

Latest SEC Filings

Date Type Title
Apr 25, 2025 10-K/A [Amend] Annual report
Apr 15, 2025 424B3 Prospectus
Apr 11, 2025 EFFECT Notice of Effectiveness
Apr 11, 2025 8-K Current Report
Apr 4, 2025 10-K/A [Amend] Annual report
Apr 2, 2025 S-3 Registration statement under Securities Act of 1933
Mar 19, 2025 10-K/A [Amend] Annual report
Mar 17, 2025 DEF 14A Other definitive proxy statements
Mar 14, 2025 8-K Current Report
Mar 14, 2025 10-K Annual Report